Payment overview · 2025
General Payments
$518.91
12 reported records · 8 companies
Healthcare provider profile · identity verified
Donna Lynn Casey, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DALLAS, TX · NPI 1689612749
Verified facts
What the public records show
CMS Open Payments records show Donna Lynn Casey, M.D. received $518.91 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $216.73 | 41.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $159.20 | 30.7% | 3 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $30.17 | 5.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.86 | 5.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.25 | 5.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.39 | 4.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.27 | 3.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.04 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $518.91 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $216.73 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $122.91 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.29 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.25 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| O-ARM Normalized: o arm |
Device | Medtronic, Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 30 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
140 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 699 | 187 |
| Atorvastatin Calcium | Atorvastatin Calcium | 476 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 320 | 101 |
| Lisinopril | Lisinopril | 296 | 91 |
| Losartan Potassium | Losartan Potassium | 202 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 198 | 66 |
| Meloxicam | Meloxicam | 192 | 73 |
| Alprazolam | Alprazolam | 166 | 67 |
| Omeprazole | Omeprazole | 162 | 65 |
| Trazodone Hcl | Trazodone Hcl | 153 | 56 |
| Mounjaro | Tirzepatide | 140 | 30 |
| Furosemide | Furosemide | 127 | 40 |
| Azithromycin | Azithromycin | 125 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 44 |
| Simvastatin | Simvastatin | 117 | 38 |
| Metformin Hcl | Metformin Hcl | 114 | 46 |
| Alendronate Sodium | Alendronate Sodium | 112 | 31 |
| Potassium Chloride | Potassium Chloride | 111 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 33 |
| Synthroid | Levothyroxine Sodium | 93 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 24 |
| Carvedilol | Carvedilol | 81 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 27 |
| Eliquis | Apixaban | 80 | 24 |
| Sertraline Hcl | Sertraline Hcl | 80 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 27 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 78 | 23 |
| Montelukast Sodium | Montelukast Sodium | 75 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 29 |
| Gabapentin | Gabapentin | 73 | 31 |
| Estradiol | Estradiol | 68 | 28 |
| Amoxicillin | Amoxicillin | 67 | 49 |
| Allopurinol | Allopurinol | 66 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 16 |
| Ozempic | Semaglutide | 50 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 50 | 22 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 49 | 16 |
| Tramadol Hcl | Tramadol Hcl | 48 | 24 |
| Ezetimibe | Ezetimibe | 44 | 15 |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 42 | 34 |
| Azelastine Hcl | Azelastine Hcl | 40 | 20 |
| Bupropion Xl | Bupropion Hcl | 40 | 12 |
| Finasteride | Finasteride | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 11 |
| Metformin Hcl Er | Metformin Hcl | 38 | 15 |
| Ondansetron Odt | Ondansetron | 38 | 28 |
| Donepezil Hcl | Donepezil Hcl | 37 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 13 |
| Valsartan | Valsartan | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | 13 |
| Meclizine Hcl | Meclizine Hcl | 35 | 18 |
| Celecoxib | Celecoxib | 34 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Myrbetriq | Mirabegron | 30 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 23 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 17 |
| Irbesartan | Irbesartan | 29 | 11 |
| Atenolol | Atenolol | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | 12 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | 17 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Mupirocin | Mupirocin | 25 | 17 |
| Spironolactone | Spironolactone | 24 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | 18 |
| Ramipril | Ramipril | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Minoxidil | Minoxidil | 20 | suppressed |
| Nystatin | Nystatin | 20 | 15 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 14 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Cephalexin | Cephalexin | 15 | 11 |
| Diazepam | Diazepam | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | 11 |
| Xofluza | Baloxavir Marboxil | 15 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Ciclopirox | Ciclopirox | 13 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $518.91 · 12 records | AstraZeneca Pharmaceuticals LP | Auvelity, EVENITY, FASENRA, JASCAYD, KISUNLA, NURTEC ODT, O-ARM, OFEV, PAXLOVID, PROLIA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error